The week in pharma: action, reaction and insight – week to August 28, 2026

By Barbara Obstoj-Cardwell. Managing editor

Significant research news last week included Regenxbio suffering a further setback in the development of RGX-121, with the US Food and Drug Administration (FDA) putting a clinical hold on its clinical trial. The FDA approved Jazz Pharmaceuticals and Zymeworks partnered cancer drug Ziihera for new indications, and Revolution Medicines won FDA approval for its Rasonque for the treatment pf pancreatic cancer. On the deal-making front, Biohaven granted a global license for its opakalim to South Korea’s SK Biopharmaceutical that could earn it $795 million.